Sunday, November 28News That Matters

EU to discuss US vaccine patent plan at Friday summit

The Daily Beast

The Next Big COVID Disaster Could Be Here

Anadolu Agency/GettyWith India’s surge in COVID-19 cases continuing to devastate the country, wary epidemiologists are trying to forecast where the novel coronavirus will strike next.Some experts are casting a wary glance toward another vast, developing country that—like India—suffers huge health disparities and uneven access to vaccines: Nigeria.With 200 million people, it’s the most populous country in West Africa and the seventh most populous country in the world.“Nigeria is actually quite vulnerable,” Ngozi Erondui, a senior research fellow at the Chatham House Center for Global Health Security in the United Kingdom, told The Daily Beast. “It has a lot of similarities to India.”The world isn’t powerless to stop COVID from devastating Nigeria the way it’s doing India. More equitable distribution of vaccines across borders could build a firewall against a surge in cases in Nigeria, as well as in other less developed countries.COVID-19 Vaccinations Are Slowing—Just in Time for the Indian VariantBut that would require the world’s richer countries to share lifesaving resources with their poorer neighbors. And if India’s tragic example proved anything, it’s that the world’s vaccine “haves” are in no hurry to help out the “have-nots” on distant continents.That said, “African” is not synonymous with “poor.” The continent is huge and diverse. Its 54 countries with their 1.2 billion people run the gamut from big to small, rich to poor, powerful to weak, democratic to authoritarian.Likewise, the African countries’ pandemic experiences have varied. South Africa—one of the richer countries on the continent—got hit hard last summer, and then again in January. Officials there have logged more than 54,000 deaths.That’s 93 fatalities per 100,000 people, a rate that’s much lower than the 175 deaths per 100,000 population the U.S. has registered, but much higher than the global average of 38 fatalities per 100,000 people.Many of the less industrialized African countries have, so far, managed to avoid the catastrophic surges in infections that have driven up death tolls in richer countries. A total of 580,000 Americans have died of COVID; only 1,600 Nigerians have died.But that doesn’t mean COVID isn’t coming for Nigeria and other African countries—it might just mean it hasn’t gotten there yet. “I see raging COVID-19 fires breaking out across the world in the coming weeks and months,” Lawrence Gostin, a Georgetown University global health expert, told The Daily Beast. “And I am most concerned about Africa.”“I see the crisis in India as a leading indicator of what is to come in other low and middle-income countries,” Gostin added.Bear in mind, India—despite its teeming cities, limited public health measures and patchwork health care—was relatively lucky until recently. The country of 1.37 billion counted just 160,000 fatal cases through March, for a rate of 11 per 100,000.Then in April, a new and more transmissible variant of the SARS-CoV-2 virus, known to geneticists as “B.1.617,” spread across the country, driving cases and deaths through the roof. In a span of just a couple of weeks, India added nearly 50,000 deaths. The fatality rate jumped to 15 per 100,000.The Frustrating Reason We’re Flying Blind on New COVID VariantsIndia’s COVID surge is ongoing as of this writing, but the trends are encouraging. The daily rates of new cases and deaths are flattening. While every indication is that tens of thousands more Indians will die before the surge ends, at least the pandemic isn’t still getting worse there.But the novel coronavirus is an opportunist. It looks for densely packed, unprotected populations. Spreading via aerosols from one person to the next, it sets up a proverbial laboratory in each body it infects. Every individual SARS-CoV-2 infection mutates every two weeks for as long as it’s active, looking for evolutionary pathways that might produce a new increasingly transmissible variant.New variants help the virus spread even faster in a self-reinforcing cycle that ends only when strong social-distancing mandates, vaccinations, the antibodies of survivors—or, more likely, a combination of all three—cut off its transmission pathways. The harder it is to socially-distance, and the lower the vaccine uptake, the longer the pathogen has to run amok.It’s no accident SARS-CoV-2 thrived in India this month. Popular religious festivals drew huge, maskless crowds. Meanwhile, India’s vaccination effort has been abysmal. The country has fully vaccinated just 3 percent of its population, compared to more than 30 percent in the United States. The global average for full vaccination is slightly more than 3 percent.Nigeria, with its teeming cities, deep poverty and ramshackle health system is, from an epidemiological standpoint, a lot like India—except worse, in some aspects. Where India at least has some domestic vaccine-manufacturers, Nigeria has none. It must import all of its doses.That helps to explain why the country has partially vaccinated just 1 percent of its population—and fully vaccinated almost no one. The government in Lagos expects to receive 84 million vaccine doses from AstraZeneca and Johnson & Johnson in coming weeks.But that’s enough to fully vaccinate just one out of five Nigerians. Vaccinating three-quarters of the population—the proportion experts say could result in “herd immunity” that blocks most transmission pathways—could take until 2022.To help Nigeria and other unprotected countries, the world’s rich countries should stop hoarding excess doses. More jabs isn’t a panacea, of course—even a country with plenty of vaccines can have trouble administering it. But while logistics, as well as hesitancy among wary citizens, could slow inoculations, a shortage of doses definitely will slow it.“The only way to know for sure how well Nigeria will administer vaccines is to ship it. Once they have a larger supply of doses, then we can see how things like distribution and hesitancy are impacting their vaccination campaign,” Shaun Truelove, an epidemiologist at the Johns Hopkins Bloomberg School of Public Health, told The Daily Beast.Global supply isn’t the biggest problem. The U.S. alone, a country with multiple competing vaccine-producers, is sitting on a stockpile of more than 60 million unused doses even as more vials arrive from factories and the vaccine-uptake rate ticks downward, especially among Republicans.It wasn’t until weeks into India’s ongoing COVID surge that the administration of President Joe Biden promised to ship some of its extra vaccines to the country. The spare jabs, from AstraZeneca, aren’t even authorized for use in the United States. To Americans, those doses aren’t just surplus—they’re useless.What’s particularly egregious about the delay in releasing surplus vaccines is that health officials anticipated this problem a year ago. Last spring, the U.N.’s World Health Organization, along with several international public-private partnerships, worked together to set up the COVID-19 Vaccines Global Access initiative, or COVAX.The idea was for rich countries to pay for vaccines for poor countries. COVAX’s goal was to deliver 100 million doses by March. It actually delivered fewer than 40 million. “This has set Nigeria and many countries up to fail,” Erondu said.The United States is part of the problem. The Trump administration refused to sign on to COVAX, a move that reflected its narrow “America-first” philosophy. The Trump White House either didn’t understand—or didn’t care—that vaccinating poor countries helps protect rich countries, too. Viruses don’t respect borders, after all.The Biden White House reversed the decision back in February. The administration pledged $4 billion in cash, making the U.S. COVAX’s biggest financial donor, albeit belatedly. In a parallel move, Biden signalled support for a controversial proposal for the World Trade Organization to suspend patent protections for COVID vaccines, in theory allowing any manufacturer in any country to produce doses.But experts are divided on whether suspending patents would result in more doses reaching the countries that need it. Meanwhile, many richer countries have been late to fulfill their COVAX pledges, piling delay on delay as the novel coronavirus targets one unprotected population after another.Nigeria is ripe for infection. But the West African country doesn’t have to suffer the same fate as India. Vaccines are available. Mechanisms exist to get it to countries that need it most. What’s lacking is a sense of urgency in the countries that have more than enough, and don’t seem to appreciate the importance of sharing it.Read more at The Daily Beast.Get our top stories in your inbox every day. Sign up now!Daily Beast Membership: Beast Inside goes deeper on the stories that matter to you. Learn more.